Purpose: We examined auxological changes in growth hormone (GH)-treated children in Italy using data from the Italian cohort of the multinational observational Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS) of pediatric patients requiring GH treatment. Methods: We studied 711 children (median baseline age 9.6 years). Diagnosis associated with short stature was as determined by the investigator. Height standard deviation score (SDS) was evaluated yearly until final or near-final height (n = 78). Adverse events were assessed in all GH-treated patients. Results: The diagnosis resulting in GH treatment was GH deficiency (GHD) in 85.5 % of patients, followed by Turner syndrome (TS 6.6 %). Median starting GH dose was higher in patients with TS (0.30 mg/kg/week) than patients with GHD (0.23 mg/kg/week). Median (interquartile range) GH treatment duration was 2.6 (0.6–3.7) years. Mean (95 % confidence interval) final height SDS gain was 2.00 (1.27–2.73) for patients with organic GHD (n = 18) and 1.19 (0.97–1.40) for patients with idiopathic GHD (n = 41), but lower for patients with TS, 0.37 (−0.03 to 0.77, n = 13). Final height SDS was >−2 for 94 % of organic GHD, 88 % of idiopathic GHD and 62 % of TS patients. Mean age at GH start was lower for organic GHD patients, and treatment duration was longer than for other groups, resulting in greater mean final height gain. GH-related adverse events occurred mainly in patients diagnosed with idiopathic GHD. Conclusions: Data from the Italian cohort of GeNeSIS showed auxological changes and safety of GH therapy consistent with results from international surveillance databases.

Efficacy and safety of growth hormone treatment in children with short stature: the Italian cohort of the GeNeSIS clinical study / Cappa, M.; Iughetti, L.; Loche, S.; Maghnie, M.; Vottero, A; GeNeSIS National Board on behalf of the GeNeSIS Italian Investigators, ; Franco, Antoniazzi; Luciano, Beccaria; Sergio, Bernasconi; Domenico, Caggiano; Manuela, Caruso-Nicoletti; Alessandra, Catucci; Francesco, Chiarelli; Stefano, Cianfarani; Annarita, Colucci; Francesca De Rienzo, ; Raffaele Di Pumpo, ; Alessandra Di Stasio, ; Giovanni, Farello; Leonardo, Felici; Pasquale, Femiano; Luigi, Garagantini; Claudia, Giavoli; Nellaaugusta, Greggio; Laura, Guazzarotti; Daniela, Larizza; Mariarosaria, Licenziati; Antonella, Lonero; Mariacristina, Maggio; Alberto, Marsciani; Patrizia, Matarazzo; Laura, Mazzanti; Beatrice, Messini; Flavia, Napoli; Annamaria, Pasquino; Laura, Perrone; Sabrina, Pilia; Alba, Pilotta; Marzia, Piran; Gabriella, Pozzobon; Predieri, Barbara; Michele, Sacco; Mariacarolina, Salerno; Antonina, Tirendi; Graziamaria, Ubertini; Silvia, Vannelli; Malgorzata, Wasniewska; Maria, Zampolli; Martina, Zanotti; Gianvincenzo, Zuccotti. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 0391-4097. - 39:6(2016), pp. 667-677. [10.1007/s40618-015-0418-0]

Efficacy and safety of growth hormone treatment in children with short stature: the Italian cohort of the GeNeSIS clinical study

Cappa M.;Iughetti L.;Barbara Predieri;
2016

Abstract

Purpose: We examined auxological changes in growth hormone (GH)-treated children in Italy using data from the Italian cohort of the multinational observational Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS) of pediatric patients requiring GH treatment. Methods: We studied 711 children (median baseline age 9.6 years). Diagnosis associated with short stature was as determined by the investigator. Height standard deviation score (SDS) was evaluated yearly until final or near-final height (n = 78). Adverse events were assessed in all GH-treated patients. Results: The diagnosis resulting in GH treatment was GH deficiency (GHD) in 85.5 % of patients, followed by Turner syndrome (TS 6.6 %). Median starting GH dose was higher in patients with TS (0.30 mg/kg/week) than patients with GHD (0.23 mg/kg/week). Median (interquartile range) GH treatment duration was 2.6 (0.6–3.7) years. Mean (95 % confidence interval) final height SDS gain was 2.00 (1.27–2.73) for patients with organic GHD (n = 18) and 1.19 (0.97–1.40) for patients with idiopathic GHD (n = 41), but lower for patients with TS, 0.37 (−0.03 to 0.77, n = 13). Final height SDS was >−2 for 94 % of organic GHD, 88 % of idiopathic GHD and 62 % of TS patients. Mean age at GH start was lower for organic GHD patients, and treatment duration was longer than for other groups, resulting in greater mean final height gain. GH-related adverse events occurred mainly in patients diagnosed with idiopathic GHD. Conclusions: Data from the Italian cohort of GeNeSIS showed auxological changes and safety of GH therapy consistent with results from international surveillance databases.
2016
28-dic-2015
39
6
667
677
Efficacy and safety of growth hormone treatment in children with short stature: the Italian cohort of the GeNeSIS clinical study / Cappa, M.; Iughetti, L.; Loche, S.; Maghnie, M.; Vottero, A; GeNeSIS National Board on behalf of the GeNeSIS Italian Investigators, ; Franco, Antoniazzi; Luciano, Beccaria; Sergio, Bernasconi; Domenico, Caggiano; Manuela, Caruso-Nicoletti; Alessandra, Catucci; Francesco, Chiarelli; Stefano, Cianfarani; Annarita, Colucci; Francesca De Rienzo, ; Raffaele Di Pumpo, ; Alessandra Di Stasio, ; Giovanni, Farello; Leonardo, Felici; Pasquale, Femiano; Luigi, Garagantini; Claudia, Giavoli; Nellaaugusta, Greggio; Laura, Guazzarotti; Daniela, Larizza; Mariarosaria, Licenziati; Antonella, Lonero; Mariacristina, Maggio; Alberto, Marsciani; Patrizia, Matarazzo; Laura, Mazzanti; Beatrice, Messini; Flavia, Napoli; Annamaria, Pasquino; Laura, Perrone; Sabrina, Pilia; Alba, Pilotta; Marzia, Piran; Gabriella, Pozzobon; Predieri, Barbara; Michele, Sacco; Mariacarolina, Salerno; Antonina, Tirendi; Graziamaria, Ubertini; Silvia, Vannelli; Malgorzata, Wasniewska; Maria, Zampolli; Martina, Zanotti; Gianvincenzo, Zuccotti. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 0391-4097. - 39:6(2016), pp. 667-677. [10.1007/s40618-015-0418-0]
Cappa, M.; Iughetti, L.; Loche, S.; Maghnie, M.; Vottero, A; GeNeSIS National Board on behalf of the GeNeSIS Italian Investigators, ; Franco, Antoniazzi; Luciano, Beccaria; Sergio, Bernasconi; Domenico, Caggiano; Manuela, Caruso-Nicoletti; Alessandra, Catucci; Francesco, Chiarelli; Stefano, Cianfarani; Annarita, Colucci; Francesca De Rienzo, ; Raffaele Di Pumpo, ; Alessandra Di Stasio, ; Giovanni, Farello; Leonardo, Felici; Pasquale, Femiano; Luigi, Garagantini; Claudia, Giavoli; Nellaaugusta, Greggio; Laura, Guazzarotti; Daniela, Larizza; Mariarosaria, Licenziati; Antonella, Lonero; Mariacristina, Maggio; Alberto, Marsciani; Patrizia, Matarazzo; Laura, Mazzanti; Beatrice, Messini; Flavia, Napoli; Annamaria, Pasquino; Laura, Perrone; Sabrina, Pilia; Alba, Pilotta; Marzia, Piran; Gabriella, Pozzobon; Predieri, Barbara; Michele, Sacco; Mariacarolina, Salerno; Antonina, Tirendi; Graziamaria, Ubertini; Silvia, Vannelli; Malgorzata, Wasniewska; Maria, Zampolli; Martina, Zanotti; Gianvincenzo, Zuccotti
File in questo prodotto:
File Dimensione Formato  
Cappa et al - 2016 J Endocrinol Invest.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 544.9 kB
Formato Adobe PDF
544.9 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1227354
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 28
social impact